The core activity of Alexion is the development and provision of life-changing therapies for people with rare diseases. The company focuses on researching, developing and delivering medicines tailored to the needs of patients with rare diseases, and strives to improve the quality of life of these individuals.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Prescription medicines for rare diseases, including Beyonttra, Kanuma, Koselugo, Soliris, Strensiq, Ultomiris and Voydeya; country availability and indications may vary.
Research and development for rare diseases
Research and development with a focus on rare diseases, new targets, modalities and technologies; focus areas in complement, genomics medicine, diagnostics and data science.
Patient support programmes
Programs for education, access to treatment, ongoing support and community connections; country-specific offerings may also include diagnosis support, transportation assistance or multidisciplinary services.
Clinical trials
Clinical trials for rare diseases with patient-centred involvement, rigorous research and access to investigational medicines as part of study participation.
Discovery partnerships
Partnerships with academia, research hospitals, government organizations, biotech companies and other scientific organizations to develop therapies for rare diseases.
Knowledge
No knowledge articles yet
Once Alexion Pharma GmbH has claimed this profile, we'll publish editorial articles and case studies here together.